NKGen Biotech, Inc. (NKGN)
OTCMKTS · Delayed Price · Currency is USD
0.0600
0.00 (0.00%)
Feb 5, 2026, 4:00 PM EST
NKGen Biotech Employees
NKGen Biotech had 26 employees as of December 31, 2024. The number of employees decreased by 37 or -58.73% compared to the previous year.
Employees
26
Change (1Y)
-37
Growth (1Y)
-58.73%
Revenue / Employee
n/a
Profits / Employee
-$905,923
Market Cap
7.84M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 26 | -37 | -58.73% |
| Dec 31, 2023 | 63 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| LakeShore Biopharma | 573 |
| Brainstorm Cell Therapeutics | 23 |
| Bioxytran | 3 |
| AccuStem Sciences | 2 |
| Synlogic | 1 |
NKGen Biotech News
- 18 days ago - NKGen Biotech Names Leading Dementia Expert Bruce L. Miller, M.D. - GlobeNewsWire
- 4 months ago - NKGen Biotech (NKGN) Clarifies OTC Market Trading Status Amid Quoting Limitations - GuruFocus
- 4 months ago - NKGen Biotech Provides Clarification on Quotation Display and Trading Status on the OTC Expert Market - GlobeNewsWire
- 4 months ago - NKGen Biotech to Present on the Use of Troculeucel for Neurodegenerative Diseases at the XXVII World Congress of Neurology - GlobeNewsWire
- 5 months ago - NKGen Biotech to Present on the Use of Troculeucel for Neurodegenerative Diseases at the 3rd China Great Bay Cell and Gene Therapy Forum - GlobeNewsWire
- 5 months ago - NKGen Biotech, Inc. Announces Completion of NKMax Co., Ltd. Acquisition; Gains Full Control of Global Manufacturing and Intellectual Property Assets - GlobeNewsWire
- 6 months ago - NKGen Biotech To Present on Allogeneic Enhanced NK Cells without Lymphodepletion in Solid Tumors at the 13th Annual Immuno-Oncology Summit - GlobeNewsWire
- 7 months ago - NKGen Biotech Presents Troculeucel Mechanism of Action with Corresponding Phase 1 Biomarker Data at the Alzheimer's Association International Conference 2025 - GlobeNewsWire